title: Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?
abstract: The without a doubt major obstacle for making DNA vaccines a commercial success is delivery. If delivery cannot be made simple, cheap and effective, DNA vaccines may not become a viable option for human use. Numerous clinical trials have confirmed that a standard needle and syringe simply do not do the job, i.e., delivering the DNA payload inside the cell. Having recognized this shortcoming, investigators have developed several new approaches for DNA vaccine delivery. In particular, new types of delivery devices, originally intended for in vitro use, have been applied for in vivo delivery. These include particle bombardment or biolistic delivery, and in vivo electroporation (EP). Importantly, both techniques seem to overcome the size barrier, meaning that they work in both mice and larger animals. In vivo EP has the key features of improved DNA uptake, increased antigen expression and a local inflammation. These factors are essential to make DNA vaccines effective in a larger host. Early data from clinical trials with DNA vaccines delivered by in vivo EP are cautiously promising. Thus, we may be entering a new era of DNA vaccination where we start to see clinical effects in humans; however, these may also be accompanied by side effects, as the vaccines become more effective.
authors.affiliation: Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Huddinge, Stockholm, Sweden.
authors.forename: Lars
authors.initials: L
authors.lastname: Frelin
authors.forename: Anette
authors.initials: A
authors.lastname: Brass
authors.forename: Gustaf
authors.initials: G
authors.lastname: Ahlén
authors.forename: Erwin Daniel
authors.initials: ED
authors.lastname: Brenndörfer
authors.forename: Margaret
authors.initials: M
authors.lastname: Chen
authors.forename: Matti
authors.initials: M
authors.lastname: Sällberg
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D018274:Electroporation / Q000379:methods*; D006801:Humans; D051379:Mice; D013678:Technology, Pharmaceutical / Q000379:methods; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology
chemical_list: D019444:Vaccines, DNA